- Investing.com
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as 89Bio Ltd. and changed its name to September 2019. The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
Pegozafermin's Promise | Explore 89bio's lead candidate in Phase III trials for MASH and SHTG, potentially unlocking billion-dollar market opportunities in liver and cardio-metabolic diseases |
Market Dynamics | Delve into the evolving landscape of MASH treatments, including the impact of GLP-1 therapies and how pegozafermin aims to differentiate itself |
Financial Outlook | Analyst targets range from $12 to $49 per share, reflecting varied assumptions about pegozafermin's potential across multiple indications |
Strategic Positioning | Learn how 89bio's pipeline-in-a-product strategy and favorable regulatory environment could shape its future in the competitive biopharmaceutical space |
Metrics to compare | ETNB | Peers Peers - average of corresponding metrics from companies closely matching ETNB: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipETNBPeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.6x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.3x | |
Upside (Analyst Target) | 0.0% | 0.0% | 44.9% | |
Fair Value Upside | Unlock | 0.0% | 5.6% | Unlock |